KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 129.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 129.69% |
| Apr 30, 2025 | 235.71% |
| Oct 31, 2024 | 3,150.00% |
| Jul 31, 2024 | 966.67% |
| Apr 30, 2024 | -465.22% |
| Jan 31, 2024 | 1,806.67% |
| Oct 31, 2023 | -98.96% |
| Jul 31, 2023 | -99.35% |
| Apr 30, 2023 | -19.77% |
| Jan 31, 2023 | -92.57% |
| Oct 31, 2022 | -46.07% |
| Jul 31, 2022 | 220.56% |
| Apr 30, 2022 | 160.61% |
| Jan 31, 2022 | 1,342.86% |
| Oct 31, 2021 | 2,638.46% |
| Jul 31, 2021 | 1,204.55% |
| Apr 30, 2021 | 312.50% |
| Oct 31, 2020 | -88.60% |
| Jul 31, 2020 | -77.55% |
| Apr 30, 2020 | -97.09% |
| Oct 31, 2019 | -48.42% |
| Jul 31, 2019 | -82.65% |
| Apr 30, 2019 | -74.63% |
| Jan 31, 2019 | -89.01% |
| Oct 31, 2018 | 333.33% |
| Jul 31, 2018 | 413.64% |
| Apr 30, 2018 | 15,385.71% |
| Jan 31, 2018 | 2,933.33% |
| Oct 31, 2017 | 183.33% |
| Jul 31, 2017 | 155.81% |
| Mar 31, 2016 | 2.22% |
| Sep 30, 2015 | 200.00% |
| Jun 30, 2015 | 5.33% |
| Mar 31, 2015 | 17,900.00% |